BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Accentia, Inc. 

5310 Cypress Center Drive #101

Tampa  Florida  33609  U.S.A.
Phone: 813-864-2554 Fax: 813-287-6642


SEARCH JOBS








 Company News
Accentia, Inc., Biovest International, Inc. Emerges from Chapter 11 Reorganization 11/17/2010 6:57:55 AM    More...
Accentia, Inc. Files Plan of Reorganization; Restructuring Supports Plans to Advance Promising Multiple Sclerosis Therapy into Late-Stage Clinical Trial 6/1/2010 6:29:18 AM    More...
Accentia, Inc.'s CEO Provides Outlook for 2008 including Update on SinuNase Phase 3 Blinded Trial Results on 80% of Patients 1/7/2008 8:31:22 AM    More...
Accentia, Inc. Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis 10/8/2007 8:09:34 AM    More...
Accentia, Inc. Says Interim Data on SinuNase Promising 6/28/2007 10:05:38 AM    More...
FDA Gives Permission To Use Very Sensitive Molecular Evidence Of Cancer In BiovaxID Pivotal Phase 3: Company Intends To Use Blood Test To File Application For Accelerated Approval 5/16/2006 12:53:14 PM    More...
Accentia, Inc. Says Cancer Vaccine Raises Survival, Shares Up 1/24/2006 10:23:51 AM    More...
Accentia Biopharmaceuticals Licenses Targeted Technology For Treatment Of Chronic Rhinosinusitis (CRS): 37 Million Affected In The US And No Approved Pharmaceutical 10/19/2005 5:10:54 PM    More...
BioDelivery Sciences International (BDSI) Announces $2,500,000 Asset Sale To Accentia, Inc. 10/19/2005 5:10:19 PM    More...
PPD, Inc. (PPDI) Makes Equity Investment In Accentia, Inc. 10/19/2005 5:09:55 PM    More...
12

//-->